Cell Therapy – Talk Bio

Galapagos Winds Down Cell Therapy Business After Failed Sale, Cuts 365 Jobs and Shutters Global Sites

1 week ago talkbio0Tagged Cell Therapy, Exit, Galapagos, layoffs, restructuring, site closures

Galapagos; cell therapy; exit; layoffs; restructuring; site closures

Recent Advances and News in In Vivo Therapeutic Technologies (2025)

2 weeks ago talkbio0Tagged Acquisitions, Autoimmune Diseases, CAR-T, Cell Therapy, drug delivery innovation, Fast Track, gene therapy, in vivo, nanoparticle delivery, Neoplasms, RNA delivery, United States Food and Drug Administration

in vivo CAR-T; cell therapy; gene therapy; RNA delivery; autoimmune disease; oncology; nanoparticle delivery; drug delivery innovation; FDA fast track; biotech acquisitions

Novo Nordisk Ends Cell Therapy Research Amid Major Restructuring

2 weeks ago talkbio0Tagged cancellations, Cell Therapy, cost-cutting, Diabetes, Novo Nordisk, Obesity, Partnership, R&D strategy, restructuring

Novo Nordisk; cell therapy; restructuring; job cuts; diabetes; cost-cutting; R&D strategy; biotech; obesity; partnership cancellations

Bristol Myers Squibb Enters In Vivo CAR-T Field with $1.5B Acquisition of Orbital Therapeutics

3 weeks ago talkbio0Tagged Acquisition, Autoimmune Diseases, Automobiles, Cell Therapy, immune system reprogramming, in vivo, Myers Squibb, NUSAP1 gene, Obstetric Delivery, Orbital Therapeutics, OTX-201, RNA medicines, RNA, Circular, T-cell therapy

Bristol Myers Squibb; Orbital Therapeutics; in vivo CAR T-cell therapy; autoimmune diseases; RNA medicines; OTX-201; cell therapy; acquisition; LNP delivery; circular RNA; immune system reprogramming

US Government Backs In Vivo Cell Therapy Startup with Major Funding

3 weeks ago talkbio0Tagged Cell Therapy, federal funding, Government, in vivo, startup, U.S.

federal funding; in vivo cell therapy; startup; immunoVec; US government

Recent Advances Shifting Perspectives in Cell Therapy (2025)

3 weeks ago talkbio0Tagged CAR T-cell, Cell Therapy, Clinical Trials, controllable, CRISPR therapies, immune cells, Labels (device), Mesenchymal Stem Cells, patient-specific therapy, Solid Neoplasm, United States Food and Drug Administration, Updates

cell therapy; CAR T-cell; solid tumors; FDA label updates; mesenchymal stem cells; CRISPR therapies; patient-specific therapy; ultrasound controllable immune cells; clinical trials

Takeda to Cut 137 Staffers After Exiting Cell Therapy Research

4 weeks ago talkbio0Tagged Cell Therapy, Exit, Industry, layoffs, Massachusetts (geographic location), pipeline shake-up, portfolio reprioritization, R&D, restructuring, strategic, Takeda

Takeda; layoffs; cell therapy exit; biotech industry; restructuring; Massachusetts R&D; strategic portfolio reprioritization; pipeline shake-up

Curtain Closes on Takeda’s Cell Therapy Efforts

4 weeks ago talkbio0Tagged Biological Factors, Cell Therapy, Gamma/Delta T-Lymphocyte, Impaired, research discontinuation, strategic shift, Takeda

Takeda; cell therapy; research discontinuation; impairment loss; gamma delta T-cell; strategic shift; biopharmaceuticals

Novo Nordisk Terminates $598M Heart Failure Cell Therapy Collaboration with Heartseed Amid Major Restructuring

4 weeks ago talkbio0Tagged Biotechnology, Cardiospermum grandiflorum, Cell Therapy, Collaboration termination, Diabetes, Heart failure, HS-001, Maziar Mike Doustdar, Nordisk, Obesity, strategic restructuring

Novo Nordisk; Heartseed; heart failure; cell therapy; HS-001; collaboration termination; strategic restructuring; Maziar Mike Doustdar; diabetes; obesity; biotechnology

ArsenalBio Lays Off 50% of Staff in Major Strategic Pivot

1 month ago talkbio0Tagged AB-2100, ArsenalBio, Cell Therapy, Clinical Trials, layoffs, Myers, restructuring, Squibb partnership, Staff

ArsenalBio; layoffs; biotech; staff reduction; restructuring; cell therapy; AB-2100; clinical trials; Bristol Myers Squibb partnership